• Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Home
Research areas
    ADME-Tox
    Biomarkers
    Cell Biology and Signalling
    Cell Sourcing - Cell Culture Technologies
    Drug Discovery
    Gene Expression - Molecular Biology
    Stem Cells
    Supplying Discovery Tools
Contact us
Meet the authors
tebu-bio's blog - Acting and reacting in life sciences and biotechnologies
  • Home
  • Research areas
    • ADME-Tox
    • Biomarkers
    • Cell Biology and Signalling
    • Cell Sourcing – Cell Culture Technologies
    • Drug Discovery
    • Gene Expression – Molecular Biology
    • Stem Cells
    • Supplying Discovery Tools
  • Contact us
  • Meet the authors
Drug Discovery

Hit-and-run cell-based therapy research with Trilink mRNA

19/10/2017 by Dimitri Szymczak, PhD 2 Comments
T cells response against cancer cell

This summer, Moffett et al. published in Nature Communications (Nature Communications – doi:10.1038/s41467-017-00505-8) a new approach for cancer therapeutic research and development based on mRNA delivery. They called it ‘Hit-and-run programming’ because of the simplicity of the method. Interestingly, the optimization of the delivery was performed with eGFP mRNA.  This post describes how TriLink’s mRNAs contribute to the simple and efficient delivery of mRNA into cells.

Continue reading
Drug Discovery

ELISA test to confirm elimination of Host Cell Proteins (HCP) from bioproductions

by Dimitri Szymczak, PhD No Comments
ELISA test for host cell proteins

Expression systems – removing their contaminants

CHO, E. Coli and Pichia are useful expression systems for drug production. This can be for proteins, enzymes or antibody productions. Research and development for therapeutic perspectives requires a high level of quality controls. Such expression systems contain +1000 host cell proteins (HCPs). A major challenge in biological component production is to remove this HCP contamination. In order to monitor removal efficiency (during protein purification, as mentioned further on in this article), Canopy Biosciences have developed and optimised HCP detection kits based on the principle of the sandwich ELISA test as illustrated below.

ELISA test to detect host cell proteins - Canopy Biosciences

Principle of the HCP Detection assay is based on sandwich ELISA test – by Canopy Biosciences at tebu-bio.com

Continue reading
Drug Discovery

cAMP signals visualized in live human pancreatic primary cells

21/07/2017 by Philippe Fixe, PhD No Comments
Montana Molecular cAMP green fluorescent sensor shows an increase of cAMP in human islets by Almaça et al. Cell 2016 DOI: http://dx.doi.org/10.1016/j.celrep.2016.11.072

In a recent publication, researchers from the University of Miami Miller School of Medicine (USA) describe that Serotonin released by human beta cell inhibits glucagon secretion by alpha cells. They demonstrated that this paracrine loop was mediated via the cAMP pathway. To do so, they captured in live human pancreatic islet cells cAMP signals using a specific fluorescent biosensor.

Continue reading
Drug Discovery

Screen for inhibitors of PD-1 signalling with a complete cellular assay system

28/10/2016 by Ali El Baya, PhD No Comments
T cell - Cancer cell CAR-T Cells, Cancer Immuno-therapy, Immune-checkpoints

Immunotherapy represents a field in Drug Discovery which is quickly developing and leading to significant progress in treatments of a number of diseases, especially cancer. The approach is based on inducing, enhancing, or surpressing an immune response. Therapeutic manipulation of immunopathways has led to promising clinical results . The first therapeutic antibodies directed against the checkpoint receptor PD-1 have been already brought to the market (Nivolumab, Pembrolizumab) by Bristol Myers Squibb and Merck/MSD respectively, and approved for the treatment of diverse cancer types.

Today, I would like to review tools to build up a comprehensive assay set up for  cell based inhibitor screening on PD-1 / PD-L1/PD-L2 binding.

Continue reading
Page 2 of 22«1234»1020...Last »
tebu-bio

LAB SERVICES OUTSOURCING

• Protein production

• Plasmid Preps

• 3D Cell Culture
LEARN MORE

Most popular posts

  • HeLa cells: Origin of this important cell line in life science research
  • From RUO to IVD - the acronym guide to reagents' intended use
  • How to choose the perfect buffer to get a pure, stabilised, functional protein
My Tweets

Top contributors

Dimitri Szymczak, PhD
Dimitri Szymczak, PhD
  • How can you get your mRNA ready in only a few weeks?
  • CleanCap: The new capping standard for self-amplifying mRNA
Frédéric Samazan
Frédéric Samazan
  • Immuno-Oncology: 6 must-haves to boost your projects
  • MagIC Beads – The future of RNA capture kits
Isabelle Nobiron, PhD
Isabelle Nobiron, PhD
  • COVID-19: relevant cell culture models
  • Immunoassay development: reliable sources of quality reagents
Isabelle Topin, PhD
Isabelle Topin, PhD
  • Antibody Purification: Tips and Tricks
  • Monoclonal antibodies – all you need to know about antibody generation
Philippe Fixe, PhD
Philippe Fixe, PhD
  • How to monitor inflammatory cytokines in anti-COVID drug discovery
  • New SARS-CoV/ACE2 inhibitor assays & small molecules for drug discovery

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Copyright © 2018 - tebu-bio - visit our main website at tebu-bio.com